Skip to main content
. 2024 Jun 27;44(7):527–540. doi: 10.1007/s40261-024-01376-w

Table 3.

Administration of letermovir (safety analysis set; N = 821)

Category Valuea
Letermovir dose and cyclosporine useb
 Letermovir 480 mg without cyclosporine 624 (76.00)
 Letermovir 240 mg without cyclosporine 53 (6.46)
 Letermovir 480 mg with cyclosporine 5 (0.61)
 Letermovir 240 mg with cyclosporine 136 (16.57)
Dosage form
 Oral tablet only 594 (72.35)
 IV only 29 (3.53)
 Switched between dosage forms 196 (23.87)
Timing of the first dose
 Median (range), day 2.0 (−10 to 100)
 Before transplantation 10 (1.22)
 On day 1c 334 (40.68)
After transplantation
 Between days > 1 and ≤ 7 219 (26.67)
 Between days > 7 and ≤ 14 145 (17.66)
 Between days > 14 and ≤ 30 94 (11.45)
 Between days > 30 and ≤ 60 10 (1.22)
 Between days > 60 and ≤ 90 6 (0.73)
 After day > 90 1 (0.12)
Administration period
 By administration route, median (range), days
  Overall 83.0 (1–521)
  Oral tablet 72.0 (1–349)
  IV 21.0 (1–117)
 Duration of administration, days
  ≤10 65 (7.92)
  > 10 to ≤ 40 143 (17.42)
  > 40 to ≤ 70 128 (15.59)
  > 70 to ≤ 100 370 (45.07)
  > 100 to ≤ 200 108 (13.15)
  > 200 5 (0.61)

IV intravenous

aValues are n (%) of patients unless otherwise specified

bAt the start of letermovir treatment

cDay of transplantation